Active	Status	Sponsor type	Region	Phase	Filter
12 Active 6 Inactive 18 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Stickland, Michael
NCT04985929: The Impact of Sildenafil on the Pulmonary Circulation in Healthy Trained and Untrained Humans	Completed	2	26	Canada	Sildenafil 50 mg, Accel-Sildenafil - 50 mg, Placebo	University of Alberta	Healthy	07/24	07/24
NCT05061368: Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD	Recruiting	2	160	Canada	Sildenafil Citrate, Placebo	University of Alberta, Canadian Institutes of Health Research (CIHR)	Chronic Obstructive Pulmonary Disease	06/25	06/25
NCT03679312: The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD	Completed	1/2	140	Canada	Nitric Oxide, Inhaled Nitric Oxide, Placebo, Medical Grade Room Air	University of Alberta, University Hospital Foundation, Canadian Lung Association, Canadian Institutes of Health Research (CIHR)	Dyspnea	11/23	11/23
NCT04231760: The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD	Not yet recruiting	1/2	80	NA	Inhaled Nitric Oxide, Placebo	University of Alberta	Chronic Obstructive Pulmonary Disease	12/25	02/26
NCT04181359: The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.	Withdrawn	1/2	40	NA	Nitric Oxide, iNO, Placebo	University of Alberta	Dyspnea	12/25	06/26
NCT06027606: Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use	Recruiting	1	90	Canada	Salbutamol 400mcg, Budesonide/formoterol, Placebo	University of Alberta	Healthy	05/25	06/25
NCT04732663: Understanding Exertional Dyspnea and Exercise Intolerance in COVID-19	Completed	N/A	64	Canada	No Intervention	University of Alberta	Covid19, Dyspnea	10/21	05/24
NCT04966637: Identifying Early Chronic Obstructive Pulmonary Disease (COPD) Using Health Administrative Data	Active, not recruiting	N/A	54028	Canada	COPD cohort	University of Alberta, Boehringer Ingelheim, Alberta Health services	Chronic Obstructive Pulmonary Disease (COPD	10/22	11/24
NCT02965963: The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise	Active, not recruiting	N/A	35	Canada	Dopamine, Metoclopramide, Placebos, Rest, Exercise - 60%, Exercise - 85%	University of Alberta, Natural Sciences and Engineering Research Council, Canada	Health	12/24	12/24
NCT03679299: Vascular Implications of a Naturally Occurring Asthma Exacerbation	Terminated	N/A	3	Canada	Observational - No intervention	University of Alberta	Asthma, Inflammation, Cardiovascular Risk Factor	06/24	06/24
HOPE-IPF, NCT02551068: High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib	Recruiting	N/A	88	Canada	60% Oxygen, Standard of Care	University of British Columbia, Boehringer Ingelheim	Idiopathic Pulmonary Fibrosis	04/24	04/25
NCT06077994: Enhanced Pulmonary Rehabilitation With Digital Remote Home Monitoring	Recruiting	N/A	74	Canada	digital Remote Patient Monitoring+BEPR+ (dRPM+), Enhanced Breathe Easy Pulmonary Rehabilitation Program (BEPR+)	University of Alberta	Chronic Obstructive Pulmonary Disease	10/24	10/24